Hancock Jaffe Laboratories- Warrants (30/05/2023) EBIT

The latest EBIT for HJLIW is $-17M as of September 2026. That compares with $-24M in the prior-year period — up 29.0% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Hancock Jaffe Laboratories- Warrants (30/05/2023)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, HJLIW's EBIT moved from $-24M to $-17M — a 29.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hancock Jaffe Laboratories- Warrants (30/05/2023)'s operating scale or balance-sheet position.

Against Healthcare companies, HJLIW currently prints $-17M for EBIT, while the sector average sits near $99B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Hancock Jaffe Laboratories- Warrants (30/05/2023)'s growth, margins, and balance sheet.

A EBIT figure of $-17M for HJLIW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting HJLIW's EBIT ($-17M), review year-over-year change from $-24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.